CKD-702 Plus Irinotecan in Gastric Cancer

National Cancer Center, Korea40 enrolled

Overview

CKD-702 is a tetravalent bispecific IgG1 targeting hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR). The investigators will test a hypothesis that CKD-702 may augment the efficacy of biweekly irinotecan as a 3L or later therapy for gastric cancer overexpressing either MET or EGFR.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Gastric Cancer

Interventions

CKD-702 in combination with irinotecanDRUG

CKD-702 and irinotecan will be intravenously administered every 2 weeks.

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Failed 2 or more lines of chemotherapy * Tumor overexpressing either MET or EGFR * Measurable lesion Exclusion Criteria: * Prior treatment with anti-MET/EGFR bispecific antibody

Locations (1)

National Cancer Center

Goyang-si, Gyeonggi-do, South Korea

RECRUITING

Outcomes

Primary Outcomes

Best objective response rate

RECIST v1.1

Time frame: Through study completion, an average of 24 weeks

Central Contacts

Hark K Kim, MD,PhD

CONTACT

+82-31-920-2238 hkim@ncc.re.kr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.